Research Article

Atypical Diabetic Foot Ulcer Keratinocyte Protein Signaling Correlates with Impaired Wound Healing

Table 1

Diabetic medications taken during the study. DFU study subjects listed by number with their prestudy medications for glycemic control. Healed indicates subjects with healed study DFU wounds at the completion of the twelve-week observation period. TIDM indicates study subject with type I DM; all other subjects are with type II DM.

Patient numberPrior therapyDFU status

1Tradjenta (linagliptin)Nonhealing
2Lantus/Humalog InsulinNonhealing
3GlimepirideNonhealing
4Glipizide; MetforminHealed
5Lantus/Humalog InsulinNonhealing
6Humalog/Humulin N InsulinNonhealing
7Humalog/Humulin N Insulin (TIDM)Nonhealing
8Humulin 70/30 InsulinNonhealing
9Glipizide/Novolog and Lantus InsulinHealed
10Glimepiride/Victoza and Invokana InsulinNonhealing
11Glyburide/Lantus and Humalog Insulin; MetforminHealed
12Glimepiride; MetforminNonhealing
13Humulin 70/30 InsulinNonhealing
14Lantus InsulinNonhealing
15Novolog and Lantus InsulinNonhealing
16Lantus and Novolog Insulin, MetforminNonhealing
17Novolin N and Novolin R Insulin; ActosNonhealing
18Glipizide, Metformin, JanuviaNonhealing